Join Chemical Week for a one hour webcast to find out the latest trends in private equity activity and how key private equity players are shifting their strategies in a challenging economic environment.
• David A. Pleasance, Senior Consulting Partner, Deloitte Consulting
• Larry D. Stern, formerly Chairman and CEO of Talecris Biotherapeutics, and Ernst and Young’s 2010 Entrepreneur of the Year in Health Sciences
• The webcast will be chaired by Robert Westervelt, Chemical Week’s Editor-in-Chief.
David will provide analysis to show how traditional value drivers for private equity investors are in flux, and how the private equity model is evolving to generate returns in an increasingly challenging economic environment. After discussing the current investment climate in the Chemical Industry, we will describe practical approaches for accelerating value creation over the investment life cycle while reducing investment risk through disciplined execution of business change.
Larry will highlight lessons learned from the acquisition, six-year transformation and then sale of Talecris at a 30 times premium for more than $4 Billion.
During this live webcast you will learn about Investment Opportunities in the Chemicals Industry: including economic trends impacting capital expenditure and growth in the chemical industry; competitive landscape across various chemical industry subsectors; innovation and sustainability in the chemical industry; and private equity investment in chemicals – past, present and future.
Discussion during the webcast also will focus on accelerating value creation in portfolio investments and will draw on practical experiences in the following areas; minimizing “day one” disruption – planning and execution; business & technology innovation to create superior returns; accelerating speed to value while reducing investment risk; and preparing for investment monetization events.
David A. Pleasance, Senior Consulting Partner, Deloitte Consulting
David is focused on leading client relationships in the chemicals and related process manufacturing industries. He has over 30 of experience working in these industries. David has been the chief architect of business strategies and led transformation programs with many global process manufacturing companies focused on strengthening competitive positioning, reshaping business portfolios, leveraging core technologies into ancillary markets and accelerating business expansion. This has included optimizing business operations in the areas of supply chain reengineering, production and manufacturing optimization, pricing strategy, customer relationship management, finance function effectiveness and enterprise risk management.
David has also advised private equity clients in the structuring of numerous M&A transactions and led the subsequent integration and transformation of the businesses. Through this work he has developed and applied an innovative “life cycle” service delivery approach which has been highly successful in accelerating and enhancing value creation while lowering portfolio investment risk
Larry D. Stern, former Chairman and CEO of Talecris Biotherapeutics
As the Chairman and CEO of Talecris Biotherapeutics, Lawrence (Larry) Stern, led the evaluation and plan that resulted in the formation of Talecris in 2005 with financial support from two private equity groups to acquire the Bayer Biologics plasma business. Larry guided the company’s transformation into an independent, industry leading global provider of plasma-derived protein therapies culminating in the company’s 2009 IPO and listing on NASDAQ. In 2010, Larry was recognized as the national winner of Ernst and Young’s Entrepreneur of the Year in Health Sciences.
Larry started his career at ARCO Chemical in 1981 where he built his skill base for 15 years in research, development and manufacturing before moving into management. He joined Bayer Corporation as the president of its Urethanes group in 2000 upon Bayer’s acquisition of Lyondell Chemical’s polyol business. Larry left Bayer in 2003 to pursue private-equity ventures, and was then able to leverage his experience at Bayer to be the successful acquirer of their Biologics’ plasma business.